Clinical Trial Update: A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 neoadjuvant trial evaluating TQB2102 for HER2-positive breast cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• TQB2102

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Conditions: HER2-positive Breast Cancer | Phase 3 | Status: RECRUITING